216 related articles for article (PubMed ID: 30787051)
1. Thymosin β 10 is overexpressed and associated with unfavorable prognosis in hepatocellular carcinoma.
Song C; Su Z; Guo J
Biosci Rep; 2019 Mar; 39(3):. PubMed ID: 30787051
[TBL] [Abstract][Full Text] [Related]
2. TMSB10 acts as a biomarker and promotes progression of clear cell renal cell carcinoma.
Pan Q; Cheng G; Liu Y; Xu T; Zhang H; Li B
Int J Oncol; 2020 May; 56(5):1101-1114. PubMed ID: 32319572
[TBL] [Abstract][Full Text] [Related]
3. A novel prognostic biomarker SPC24 up-regulated in hepatocellular carcinoma.
Zhu P; Jin J; Liao Y; Li J; Yu XZ; Liao W; He S
Oncotarget; 2015 Dec; 6(38):41383-97. PubMed ID: 26515591
[TBL] [Abstract][Full Text] [Related]
4. Thymosin beta 10 is a key regulator of tumorigenesis and metastasis and a novel serum marker in breast cancer.
Zhang X; Ren D; Guo L; Wang L; Wu S; Lin C; Ye L; Zhu J; Li J; Song L; Lin H; He Z
Breast Cancer Res; 2017 Feb; 19(1):15. PubMed ID: 28179017
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-608 acts as a prognostic marker and inhibits the cell proliferation in hepatocellular carcinoma by macrophage migration inhibitory factor.
Wang K; Liang Q; Wei L; Zhang W; Zhu P
Tumour Biol; 2016 Mar; 37(3):3823-30. PubMed ID: 26474589
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
Shi XM; Teng F
Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
[TBL] [Abstract][Full Text] [Related]
7. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma.
Zhang XJ; Su YR; Liu D; Xu DB; Zeng MS; Chen WK
J Surg Res; 2014 Dec; 192(2):487-93. PubMed ID: 24974154
[TBL] [Abstract][Full Text] [Related]
8. Elevated UHRF1 expression contributes to poor prognosis by promoting cell proliferation and metastasis in hepatocellular carcinoma.
Liu X; Ou H; Xiang L; Li X; Huang Y; Yang D
Oncotarget; 2017 Feb; 8(6):10510-10522. PubMed ID: 28060737
[TBL] [Abstract][Full Text] [Related]
9. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
10. TMSB10, a potential prognosis prediction biomarker, promotes the invasion and angiogenesis of gastric cancer.
Yan Z; Yan Q; Song Y; Wang L
J Gastroenterol Hepatol; 2021 Nov; 36(11):3102-3112. PubMed ID: 34114679
[TBL] [Abstract][Full Text] [Related]
11. Fibulin-5 inhibits hepatocellular carcinoma cell migration and invasion by down-regulating matrix metalloproteinase-7 expression.
Tu K; Dou C; Zheng X; Li C; Yang W; Yao Y; Liu Q
BMC Cancer; 2014 Dec; 14():938. PubMed ID: 25494879
[TBL] [Abstract][Full Text] [Related]
12. TRIM26 functions as a novel tumor suppressor of hepatocellular carcinoma and its downregulation contributes to worse prognosis.
Wang Y; He D; Yang L; Wen B; Dai J; Zhang Q; Kang J; He W; Ding Q; He D
Biochem Biophys Res Commun; 2015 Jul; 463(3):458-65. PubMed ID: 26043685
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.
Zhang Y; Liu X; Liu L; Chen J; Hu Q; Shen S; Zhou Y; Chen S; Xue C; Cui G; Yu Z
Dis Markers; 2020; 2020():2514090. PubMed ID: 32399086
[TBL] [Abstract][Full Text] [Related]
14. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
15. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
16. MiR-122 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma by targeting Snail1 and Snail2 and suppressing WNT/β-cadherin signaling pathway.
Jin Y; Wang J; Han J; Luo D; Sun Z
Exp Cell Res; 2017 Nov; 360(2):210-217. PubMed ID: 28890291
[TBL] [Abstract][Full Text] [Related]
17. MIR210HG predicts poor prognosis and functions as an oncogenic lncRNA in hepatocellular carcinoma.
Wang Y; Li W; Chen X; Li Y; Wen P; Xu F
Biomed Pharmacother; 2019 Mar; 111():1297-1301. PubMed ID: 30841443
[TBL] [Abstract][Full Text] [Related]
18. High expression of Golgi phosphoprotein-3 is associated with poor survival in patients with hepatocellular carcinoma.
Hu GS; Li YQ; Yang YM; Shi W; Liao AJ; Yao YH; Zeng B; Yuan J
Tumour Biol; 2014 Sep; 35(9):8625-32. PubMed ID: 24867097
[TBL] [Abstract][Full Text] [Related]
19. Fanconi Anemia Complementation Group E, a DNA Repair-Related Gene, Is a Potential Marker of Poor Prognosis in Hepatocellular Carcinoma.
Takahashi J; Masuda T; Kitagawa A; Tobo T; Nakano Y; Abe T; Ando Y; Kosai K; Kobayashi Y; Matsumoto Y; Yoshizumi T; Mori M; Mimori K
Oncology; 2022; 100(2):101-113. PubMed ID: 34724663
[TBL] [Abstract][Full Text] [Related]
20. RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma.
Shang R; Wang J; Sun W; Dai B; Ruan B; Zhang Z; Yang X; Gao Y; Qu S; Lv X; Tao K; Wang L; Dou K; Wang D
Tumour Biol; 2016 Apr; 37(4):5097-105. PubMed ID: 26546438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
